Wang Q, Fu Y W, Wang Y Q, Ai H, Yuan F F, Wei X D, Song Y P
Department of Hematology, The Anti- Cancer Hospital Affiliated with Zhengzhou University, Zhengzhou 450008, China.
Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):853-855. doi: 10.3760/cma.j.issn.0253-2727.2019.10.011.
To explore the availability and safety of fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Four acute leukemia patients suffered from refractory diarrhea after allo-HSCT. One of them was refractory intestinal infection, the others were intestinal graft versus host disease. One or two doses of fecal microbiota, 3.4-6.0 U for one dose, were infused via nasal-jejunal tube. The curative effect and side effects were reviewed. Three cases achieved complete remission while 1 was stable disease. The side effects included fever, abdominal pain and diarrhea, which all were Ⅰ grade. Fecal microbiota transplantation was effective and safe for refractory diarrhea after allo-HSCT.
探讨异基因造血干细胞移植（allo-HSCT）后难治性腹泻患者粪便微生物群移植的可行性和安全性。4例急性白血病患者在allo-HSCT后出现难治性腹泻。其中1例为难治性肠道感染，其他为肠道移植物抗宿主病。通过鼻空肠管输注一或两剂粪便微生物群，一剂为3.4-6.0 U。回顾了疗效和副作用。3例完全缓解，1例病情稳定。副作用包括发热、腹痛和腹泻，均为Ⅰ级。粪便微生物群移植对allo-HSCT后难治性腹泻有效且安全。
